Roivant Sciences Stock Rebounds on Analyst Optimism
25
2
BTCCSquare news:
Roivant Sciences (ROIV) surged nearly 4% Tuesday, outpacing the broader market's 1.1% gain, after Leerink Partners analyst David Risinger raised his price target to $18. The bullish revision reflects confidence in the biotech's share repurchase program and its phase 3 trial for brepocitinib, a potential treatment for dermatomyositis.
Investors shrugged off Monday's post-earnings slump as Risinger maintained his outperform rating. His Optimism hinges on anticipated trial results due later this year, signaling potential upside for the healthcare stock. The rebound demonstrates how analyst sentiment can quickly shift market dynamics for clinical-stage biotechs.
By:
